Rep Pract Oncol Radiother
January 2014
Background: The limits of TDF (time, dose, and fractionation) and linear quadratic models have been known for a long time. Medical physicists and physicians are required to provide fast and reliable interpretations regarding delivered doses or any future prescriptions relating to treatment changes.
Aim: We, therefore, propose a calculation interface under the GNU license to be used for equivalent doses, biological doses, and normal tumor complication probability (Lyman model).
Purpose: Radiotherapy is an important treatment for prostate cancer. During treatment sessions, bladder and rectal repletion is difficult to quantify and cannot be measured with a single and initial CT scan acquisition. Some methods, such as image-guided radiation therapy and dose-guided radiation therapy, aim to compensate this missing information through periodic CT acquisitions.
View Article and Find Full Text PDFBackground: Glioblastoma multiform (GBM) is the most common and most aggressive type of primary brain tumour in humans. It has a very poor prognosis despite multi-modality treatments consisting of open craniotomy with surgical resection, followed by chemotherapy and/or radiotherapy. Recently, a new treatment has been proposed - Boron Neutron Capture Therapy (BNCT) - which exploits the interaction between Boron-10 atoms (introduced by vector molecules) and low energy neutrons produced by giant accelerators or nuclear reactors.
View Article and Find Full Text PDFJ Int Assoc Physicians AIDS Care (Chic)
June 2009
HIV-1 infection has increased among women in recent years. The HIV-1 env gene (structural gene) has the greatest variation in all the HIV gene regions. In this study, 58 samples from infants infected with HIV-1 via perinatal transmission were analyzed.
View Article and Find Full Text PDFPurpose: Comparative study between a classical conformational prostate radiotherapy (3DRTC) and two arctherapy techniques, a coplanar (AT-C) and the other non-coplanar (AT-NC).
Patients And Methods: The comparison has been made retrospectively on 30 patients with localized prostate cancer (T2-T3a, PSA< 20 ng/ml, Gleason<7). The objective criteria for comparison were the NTCP, EUD, and dose volume (on DVH), for the volumes of bladder wall, rectal wall, femoral heads, small bowel, prostate (P) and seminal vesicles (VS).